MQS Management LLC Purchases New Shares in Pfizer Inc. (NYSE:PFE)

MQS Management LLC acquired a new stake in Pfizer Inc. (NYSE:PFE) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 13,853 shares of the biopharmaceutical company’s stock, valued at approximately $401,000.

Several other large investors have also made changes to their positions in PFE. Olistico Wealth LLC acquired a new position in Pfizer during the second quarter worth about $25,000. MFA Wealth Advisors LLC purchased a new position in Pfizer during the second quarter worth approximately $29,000. Quarry LP acquired a new position in Pfizer during the second quarter worth $31,000. Financial Connections Group Inc. purchased a new stake in Pfizer in the 2nd quarter valued at $34,000. Finally, ESL Trust Services LLC acquired a new stake in shares of Pfizer in the 1st quarter worth $37,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Pfizer

In related news, Director Scott Gottlieb bought 1,000 shares of the stock in a transaction dated Wednesday, October 30th. The stock was acquired at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the acquisition, the director now owns 10,000 shares in the company, valued at approximately $282,400. This represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.06% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

PFE has been the subject of several recent analyst reports. Wells Fargo & Company raised their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Citigroup initiated coverage on Pfizer in a report on Friday, October 25th. They issued a “neutral” rating and a $30.00 price objective on the stock. Sanford C. Bernstein initiated coverage on Pfizer in a research note on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price for the company. StockNews.com raised Pfizer from a “buy” rating to a “strong-buy” rating in a research note on Tuesday. Finally, UBS Group increased their target price on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. Eight investment analysts have rated the stock with a hold rating, five have given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer currently has a consensus rating of “Moderate Buy” and an average target price of $33.58.

Pfizer Stock Performance

Shares of Pfizer stock opened at $26.72 on Thursday. The business has a 50-day simple moving average of $28.80 and a 200-day simple moving average of $28.68. The company has a market cap of $151.42 billion, a PE ratio of 36.11, a P/E/G ratio of 0.83 and a beta of 0.67. Pfizer Inc. has a one year low of $25.20 and a one year high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. The business had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The company’s revenue was up 31.2% on a year-over-year basis. During the same period last year, the business earned ($0.17) EPS. On average, equities research analysts forecast that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be paid a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 6.29%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s payout ratio is 227.03%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.